Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | NTRK1 | P04629 | 2/20 | 0.36 |
| ▸ | S1PR5 | Q9H228 | 8/20 | 0.35 |
| ▸ | S1PR4 | O95977 | 7/20 | 0.35 |
| ▸ | PARP1 | P09874 | 2/20 | 0.35 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.34 |
| ▸ | GSK3B | P49841 | 1/20 | 0.33 |
| ▸ | HPGDS | O60760 | 1/20 | 0.33 |
| ▸ | JAK2 | O60674 | 1/20 | 0.33 |
| ▸ | JAK3 | P52333 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14075027 | 0.86 | GSK3B (0.44) | KMT2AS1PR5S1PR4GSK3B | |
| SCHEMBL4137031 | 0.81 | S1PR5 (0.42) | SMN1; SMN2S1PR5S1PR4GSK3B | |
| SCHEMBL6426335 | 0.77 | KMT2A (0.46) | SMN1; SMN2MEN1KMT2A | |
| SCHEMBL5030016 | 0.75 | TSHR (0.40) | SMN1; SMN2KMT2A | |
| SCHEMBL6427096 | 0.75 | MAPT (0.47) | SMN1; SMN2MEN1KMT2A | |
| SCHEMBL4144980 | 0.73 | HPGD (0.47) | — | |
| SCHEMBL4149014 | 0.73 | RAB9A (0.52) | SMN1; SMN2MEN1KMT2AGSK3B | |
| SCHEMBL4335983 | 0.72 | MEN1 (0.51) | SMN1; SMN2MEN1KMT2ANTRK1PARP1 | |
| SCHEMBL4331235 | 0.72 | MEN1 (0.46) | SMN1; SMN2MEN1KMT2APARP1GSK3B | |
| SCHEMBL4333966 | 0.72 | MEN1 (0.46) | SMN1; SMN2MEN1KMT2APARP1GSK3B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7429609-B2 | Pyrazole compound and medicinal composition containing the same | EISAI R & D MANAGEMENT CO., LTD. (JP) | 2008-09-30 | — | — | US | disclosed |
| US-7429609-B2 | Pyrazole compound and medicinal composition containing the same | EISAI R & D MANAGEMENT CO., LTD. (JP) | 2008-09-30 | — | — | US | disclosed |
| US-20050261339-A1 | Pyrazole compound and medicinal composition containing the same | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2005-11-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050261339-A1 | Pyrazole compound and medicinal composition containing the same | CNKSR1, NR3C2, CSNK2B | SMN1; SMN2 3772/4885MEN1 4470/4885KMT2A 741/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.